China Meheco(SH:600056) Ge Long Hui A P P·2025-12-30 09:15Core Viewpoint - China Medical (600056.SH) aims to enhance its comprehensive strength in pharmaceutical R&D innovation by acquiring a 70% stake in Shanghai Zezheng Pharmaceutical Technology Co., Ltd. for RMB 525 million, thereby addressing current R&D system shortcomings and integrating the entire industry chain from R&D to production [1] Group 1 - The acquisition will be funded through the company's own and/or self-raised funds [1] - After the transaction, Zezheng Pharmaceutical will become a wholly-owned subsidiary of China Medical, included in the consolidated financial statements [1] - This move is expected to strengthen the company's capabilities in pharmaceutical R&D, facilitating deep integration in technology, market, and resources [1] Group 2 - The transaction aims to enhance the company's layout in various fields, including generic drug research, improved new drug research, and innovative drug research [1] - The integration is intended to create a collaborative development framework among pharmaceutical R&D, industrial production, and commercial operations [1] - This strategic acquisition is anticipated to further improve the competitiveness of the listed company in the pharmaceutical industry [1]